Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials by Reich, Kristian, Prof, Papp, Kim A, MD, Blauvelt, Andrew, MD, Tyring, Stephen K, Prof, Sinclair, Rodney, Prof, Thaçi, Diamant, Prof, Nograles, Kristine, MD, Mehta, Anish, BA, Cichanowitz, Nicole, MSJ, Li, Qing, PhD, Liu, Kenneth, PhD, La Rosa, Carmen, MD, Green, Stuart, MD, Kimball, Alexa B, Prof

Get full text

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled t... by Leonardi, Craig L, Prof, Kimball, Alexa B, MD, Papp, Kim A, MD, Yeilding, Newman, MD, Guzzo, Cynthia, MD, Wang, Yuhua, PhD, Li, Shu, MS, Dooley, Lisa T, DrPH, Gordon, Kenneth B, Dr

Get full text